Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.

van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404.

View in: PubMed

collapse authors with profiles